8-K: Waters Shareholders Approve BD Biosciences Merger

Waters Corporation shareholders overwhelmingly approved the issuance of shares for the proposed combination with BD's Biosciences & Diagnostic Solutions business, with the transaction expected to close on February 9, 2026.

Summary

• A special meeting of shareholders was held on January 27, 2026, where approximately 54,072,110 shares of Waters Common Stock, representing about 90.80% of all eligible shares, were present or represented by proxy.
• The Share Issuance Proposal, concerning the issuance of Waters Common Stock pursuant to the Merger Agreement, was approved with 53,910,265 votes 'For', 136,468 'Against', and 25,377 'Abstain', representing approximately 99% of votes cast.
• The Adjournment Proposal was rendered moot and not called for a vote due to the approval of the Share Issuance Proposal.
• Becton, Dickinson and Company (BD) has received a favorable Private Letter Ruling from the Internal Revenue Service regarding the U.S. federal income tax consequences of the transaction.
• Waters and BD have obtained all required regulatory approvals for the transaction.
• The transaction is expected to close on February 9, 2026, subject to the satisfaction or waiver of remaining customary closing conditions.
• Waters' Q4 2025 financial results conference call has been rescheduled to Monday, February 9, 2026, at 8:30 a.m. ET, to coincide with the expected closing of the transaction.

Sentiment

Score: 8

Explanation: The filing reports the successful shareholder approval and all regulatory clearances for a significant merger, indicating strong progress towards a strategic growth initiative. The tone is positive and forward-looking, despite standard risk disclosures.

Positives

• Overwhelming shareholder approval for the share issuance, with approximately 99% of votes cast in favor, demonstrating strong investor confidence.
• Receipt of a favorable Private Letter Ruling from the IRS regarding the U.S. federal income tax consequences of the transaction.
• All required regulatory approvals have been obtained, removing significant hurdles to the transaction's completion.
• The transaction is on track to close as expected on February 9, 2026, providing clarity and certainty.
• Management anticipates creating meaningful value for patients, customers, employees, and shareholders alike through the combined entity.

Risks

• One or more closing conditions to the transaction may not be satisfied or waived on a timely basis or at all.
• The proposed transaction may not be completed on the terms or in the timeframe expected, or at all.
• Unexpected costs, charges, or expenses may result from the proposed transaction.
• Uncertainty exists regarding the expected financial performance of the combined company following completion of the proposed transaction.
• Failure to realize the anticipated benefits of the proposed transaction, including due to delays in completion or integration of the businesses.
• The combined company may face challenges in implementing its business strategy.
• Difficulties and delays may occur in the combined company achieving revenue and cost synergies.
• Inability of the combined company to retain and hire key personnel.
• The occurrence of any event that could give rise to termination of the proposed transaction.
• Stockholder litigation or other litigation, settlements, or investigations in connection with the proposed transaction may affect its timing or occurrence or result in significant costs.
• Evolving legal, regulatory, and tax regimes could impact the transaction or combined entity.
• Changes in general economic and/or industry-specific conditions or volatility from tariffs.
• Actions by third parties, including government agencies, could affect the transaction.
• The anticipated tax treatment of the proposed transaction may not be obtained.
• Greater than expected difficulty in separating the business of SpinCo from the other businesses of BD.
• Disruption of management time from ongoing business operations due to the pendency of the proposed transaction.
• Other effects of the transaction's pendency on relationships with employees, customers, suppliers, or other counterparties.

Future Outlook

The transaction is expected to close on February 9, 2026, positioning the combined entity as a differentiated leader in life sciences and diagnostics. Management anticipates ushering in a new chapter of growth and innovation, creating meaningful value for patients, customers, employees, and shareholders. The combined company aims for strong future operating and financial performance, market growth, and product success.

Management Comments

• "We appreciate the continued support of our shareholders as we move closer to completing this transaction."
• "With this milestone complete, our focus is on closing the transaction and ushering in the next chapter of growth and innovation as a differentiated leader in life sciences and diagnostics."
• "We look forward to creating meaningful value for patients, customers, employees, and shareholders alike." Udit Batra, Ph.D., President and Chief Executive Officer, Waters Corporation

Industry Context

This announcement signifies a major step towards the strategic combination of Waters Corporation, a leader in analytical instruments and separation technologies, with BD's Biosciences & Diagnostic Solutions business. This merger is poised to create a more comprehensive and diversified entity within the life sciences and diagnostics industry, aiming to enhance offerings and drive innovation in a sector critical for healthcare and scientific advancement.

Legal Proceedings

• The filing notes a risk that stockholder litigation in connection with the proposed transaction or other litigation, settlements, or investigations may affect the timing or occurrence of the proposed transaction or result in significant costs of defense, indemnification, and liability.

Stakeholder Impact

• Shareholders: Will receive shares of Waters Common Stock, with potential for value creation from the combined entity's growth and innovation.
• Patients and Customers: Expected to benefit from the combined company's enhanced offerings and leadership in life sciences and diagnostics.
• Employees: Potential for disruption of management time due to the transaction and risks related to retaining and hiring key personnel in the combined company.
• Suppliers and Counterparties: Risks related to the disruption of relationships due to the pendency of the proposed transaction.

Next Steps

• Closing of the transaction on February 9, 2026, subject to remaining customary closing conditions.
• Waters to release Q4 2025 financial results and hold a conference call on February 9, 2026, at 8:30 a.m. ET.
• Integration of the businesses of Waters and SpinCo following the transaction close.
• Implementation of the combined company's business strategy to achieve anticipated benefits and synergies.

Key Dates

Recommendation

The filing confirms the successful progression of a significant strategic merger, with shareholder and regulatory approvals secured and a clear closing date. This reduces uncertainty surrounding the transaction. However, the inherent risks associated with integration, achieving synergies, and potential litigation, as detailed in the forward-looking statements, warrant a 'hold' position. Investors should monitor the actual closing, subsequent integration progress, and the combined entity's initial financial performance before making further investment decisions. The positive news is largely priced in, and the remaining risks suggest caution rather than an immediate 'buy' or 'sell.'

Keywords

Waters Corporation, Becton Dickinson, BD Biosciences, Diagnostic Solutions, Merger, Acquisition, Shareholder Vote, SEC Filing, 8-K, Life Sciences, Analytical Instruments, Corporate Governance, Spin-off, Reverse Morris Trust